ArticleInternational journal of women's health2025
Predictive Value of Second Trimester HbA1c for Adverse Perinatal Outcomes: A Comparative Study in Diabetic and Non-Diabetic Pregnancies.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Second-trimester glycated hemoglobin (HbA1c) has been proposed as a marker of adverse pregnancy outcomes, yet its predictive value across gestational diabetes mellitus (GDM), pregestational diabetes mellitus (PGDM), and non-diabetic pregnancies remains unclear. This study assessed whether mid-pregnancy HbA1c predicts adverse perinatal outcomes and identified a clinically meaningful threshold. Materials and Methods: This retrospective cohort included 460 singleton pregnancies delivered between January 2021 and January 2025 at Bursa City Hospital. Participants were categorized as GDM (n = 203), PGDM (n = 58), or healthy controls (n = 199). HbA1c was measured at 24-28 gestational weeks. An ROC-derived cut-off of 5.3% for predicting macrosomia (>4000 g) was used for subgroup analyses. Perinatal outcomes included gestational age at delivery, delivery mode, birth weight, Apgar scores, and neonatal intensive care unit (NICU) admission. Correlation, ROC, and multivariate logistic regression analyses were performed. Results: Median HbA1c levels were highest in the PGDM group (6.50%), followed by GDM (5.36%) and controls (4.93%) (p = 0.038). Women with HbA1c >5.3% had higher rates of preterm birth (p = 0.005), cesarean delivery (p = 0.012), and macrosomia (p = 0.004). ROC analysis showed moderate predictive ability for macrosomia (AUC = 0.642), preterm birth (AUC = 0.602), and cesarean delivery (AUC = 0.562). In multivariate analysis, maternal BMI independently predicted macrosomia (OR = 1.07; 95% CI: 1.01-1.14; p = 0.02), whereas HbA1c showed a positive but nonsignificant association (OR = 1.35; p = 0.13). Conclusion: Second-trimester HbA1c values above 5.3% were associated with increased risks of preterm birth, cesarean delivery, and macrosomia. Although HbA1c did not independently predict adverse outcomes after adjustment, it may serve as a useful adjunct biomarker for perinatal risk stratification and could contribute to multivariable prediction models.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.